U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H27N3O4
Molecular Weight 481.5424
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACEBILUSTAT

SMILES

OC(=O)C1=CC=C(CN2C[C@@H]3C[C@H]2CN3CC4=CC=C(OC5=CC=C(C=C5)C6=NC=CO6)C=C4)C=C1

InChI

InChIKey=GERJIEKMNDGSCS-DQEYMECFSA-N
InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)/t24-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula C29H27N3O4
Molecular Weight 481.5424
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Acebilustat (formerly CTX-4430) is an investigational oral drug under development by Celtaxsys. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate‐limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils. Acebilustat is currently being tested in Phase 2 clinical trial as a modulator of inflammation in patients with cystic fibrosis (CF). The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan drug status to acebilustat as a treatment for cystic fibrosis.

Approval Year

PubMed

PubMed

TitleDatePubMed
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis.
2017 Jan
Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction.
2017 Jan
EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.
2018 Sep

Sample Use Guides

Seventeen patients with mild to moderate cystic fibrosis were enrolled and randomized into groups receiving placebo or doses of 50 mg or 100 mg acebilustat administered orally, once daily for 15 days. Sputum neutrophil counts were reduced by 65% over baseline values in patients treated with 100 mg acebilustat.
Route of Administration: Oral
IC50 of acebilustat for inhibition of LTB4 production in human whole blood is 31 ng/ml, ∼0.064 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:51:01 GMT 2023
Edited
by admin
on Sat Dec 16 10:51:01 GMT 2023
Record UNII
J64RI4D29U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACEBILUSTAT
INN   WHO-DD  
INN  
Official Name English
Acebilustat [WHO-DD]
Common Name English
4-(((1S,4S)-5-((4-(4-(2-OXAZOLYL)PHENOXY)PHENYL)METHYL)-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)METHYL)-BENZOIC ACID
Systematic Name English
BENZOIC ACID, 4-(((1S,4S)-5-((4-(4-(2-OXAZOLYL)PHENOXY)PHENYL)METHYL)-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)METHYL)-
Systematic Name English
EP-501
Code English
CTX-4430
Code English
acebilustat [INN]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/14/1363
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
FDA ORPHAN DRUG 432114
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
Code System Code Type Description
EVMPD
SUB181430
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
PUBCHEM
68488178
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
SMS_ID
100000167045
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
NCI_THESAURUS
C169757
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
INN
10204
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
DRUG BANK
DB15385
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
CAS
943764-99-6
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
FDA UNII
J64RI4D29U
Created by admin on Sat Dec 16 10:51:01 GMT 2023 , Edited by admin on Sat Dec 16 10:51:01 GMT 2023
PRIMARY
Related Record Type Details
LABELED -> NON-LABELED
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY